🇺🇸 FDA
Patent

US 10563204

Methods of treating cancer harboring hemizygous loss of TP53

granted A61KA61K31/7088A61K31/7105

Quick answer

US patent 10563204 (Methods of treating cancer harboring hemizygous loss of TP53) held by The Board of Regents of the University of Texas System expires Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Feb 18 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 13 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K31/7088, A61K31/7105, A61K45/06, A61K47/6831